Amicus Therapeutics, Inc. 0HF9.L Stock
Amicus Therapeutics, Inc. Price Chart
Amicus Therapeutics, Inc. 0HF9.L Financial and Trading Overview
| Amicus Therapeutics, Inc. stock price | 10.77 USD |
| Previous Close | 13.31 USD |
| Open | 0 USD |
| Bid | 0 USD x N/A |
| Ask | 0 USD x N/A |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 13.73 USD |
| Volume | 234 USD |
| Avg. Volume | 1.44K USD |
| Market Cap | 38.11M USD |
| Beta (5Y Monthly) | 0.797183 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.973 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0HF9.L Valuation Measures
| Enterprise Value | 3.82B USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.11314959 |
| Price/Book (mrq) | 35.911602 |
| Enterprise Value/Revenue | 11.34 |
| Enterprise Value/EBITDA | -22.908 |
Trading Information
Amicus Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.797183 |
| 52-Week Change | 43.83% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 13.73 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 11.83 USD |
| 200-Day Moving Average | 11.53 USD |
0HF9.L Share Statistics
| Avg. Volume (3 month) | 1.44K USD |
| Avg. Daily Volume (10-Days) | 3.4K USD |
| Shares Outstanding | 189.29M |
| Float | 208.4M |
| Short Ratio | N/A |
| % Held by Insiders | 0.86% |
| % Held by Institutions | 105.76% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -60.64% |
| Operating Margin (ttm) | -51.041% |
| Gross Margin | 88.72% |
| EBITDA Margin | -49.50% |
Management Effectiveness
| Return on Assets (ttm) | -14.066% |
| Return on Equity (ttm) | -119.72% |
Income Statement
| Revenue (ttm) | 336.79M USD |
| Revenue Per Share (ttm) | 1.16 USD |
| Quarterly Revenue Growth (yoy) | 9.59% |
| Gross Profit (ttm) | 290.63M USD |
| EBITDA | -166712000 USD |
| Net Income Avi to Common (ttm) | -204240000 USD |
| Diluted EPS (ttm) | -0.973 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 267.11M USD |
| Total Cash Per Share (mrq) | 0.94 USD |
| Total Debt (mrq) | 452.01M USD |
| Total Debt/Equity (mrq) | 440.67 USD |
| Current Ratio (mrq) | 2.888 |
| Book Value Per Share (mrq) | 0.362 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -126329000 USD |
| Levered Free Cash Flow (ttm) | -66124500 USD |
Profile of Amicus Therapeutics, Inc.
| Country | United Kingdom |
| State | PA |
| City | Philadelphia |
| Address | 3675 Market Street |
| ZIP | 19104 |
| Phone | 215 921 7600 |
| Website | https://amicusrx.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 484 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Amicus Therapeutics, Inc. Stock
What is a current 0HF9.L stock price?
Amicus Therapeutics, Inc. 0HF9.L stock price today per share is 10.77 USD.
How to purchase Amicus Therapeutics, Inc. stock?
You can buy 0HF9.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amicus Therapeutics, Inc.?
The stock symbol or ticker of Amicus Therapeutics, Inc. is 0HF9.L.
How many shares does Amicus Therapeutics, Inc. have in circulation?
The max supply of Amicus Therapeutics, Inc. shares is 2.93M.
What is Amicus Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Amicus Therapeutics, Inc. PE Ratio is now.
What was Amicus Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Amicus Therapeutics, Inc. EPS is -0.973 USD over the trailing 12 months.